OmidriaTM granted pass-through reimbursement status from CMS
Omeros announced that it has received transitional pass-through status for its lead product Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% from the Center for Medicare & Medicaid Services, the federal agency that administers the Medicare program. October 30, 2014